Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the launch of Medarex/Bristol-Myers Squibb's ipilimumab and Pfizer's ticilimumab will significantly impact the market for treatment of malignant melanoma. According to the new report entitled New Therapies Entering the Market May Raise Hurdles: A Malignant Melanoma Study, both ipilimumab and ticilimumab offer clinicians more freedom in treatment design based on the individual patient's performance status.

The approval of ipilimumab and ticilimumab will have a significant impact on the stage IV malignant melanoma market.

"Although ipilimumab will initially target relapsing patients and ticilimumab will be used as a first-line monotherapy, ipilimumab will move into the first-line setting in combination with the commonly used chemotherapy agent dacarbazine," said Mohamed Muhsin, analyst at Decision Resources. "The availability of both agents, approved for different regimens (ticilimumab as a monotherapy; ipilimumab in combination), will give clinicians more freedom in deciding whether to incorporate a chemotherapy agent based on the individual patient's performance status, and it will help them avoid the reimbursement issues associated with prescribing off-label."

About New Therapies Entering the Market May Raise Hurdles: A Malignant Melanoma Study

New Therapies Entering the Market May Raise Hurdles: A Malignant Melanoma Study covers the current and future state of the malignant melanoma drug market. The report includes the following:

  -- More than 3,000 physician responses that define drug attributes that      drive prescription now and in the future.      - Clinical end point tradeoffs that are most influential to physicians.      - Areas of unmet need with highest potential.      - Benchmark trial results for specific drug opportunities.      - Patient share potential for emerging therapies and target product        profiles.    -- Decision Resources proprietary analysis of commercial factors that      accelerate or constrain a drug's market potential.      - Promotion: DTC spend, detailing intensity.      - Reimbursement: formulary tier, prior approval restriction, quantity        limits.      - Labeling: black box warnings, approved patient segments,        contraindications.      - Competition: order of entry, pricing, generic entry, pipeline sales        forecast.      - Medical practice: decision trees, treating physician type, line of        therapy.      - Comparisons of the key clinical attributes of current and emerging        therapies in the areas of efficacy, safety, and delivery.      - Analysis and supporting data that identify the clinical "Gold        Standard" now and over the next ten years.      - Key insights as to which clinical end points have the greatest        influence on physician decision-making.  

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Oncologists Not Yet Ready to Use GlaxoSmithKline's Tykerb as a Replacement for Genentech/Roche's Herceptin in the Treatment of Breast Cancer

View Now